Precision BioSciences, Inc.
NASDAQ:DTILBiotechnology
+$0.11 today
- Market cap
- $198.34M
- Beta
- 1.28
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$3.47
Volume 0.37M
Average 0.31M
DTIL EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Precision BioSciences, Inc.NASDAQ: DTIL
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$17.49M, compared with -$19.51M a year earlier. Trailing-twelve-month EBITDA was -$40.42M.
Context
- EBITDA amounted to 123.8% of revenue in FY2025, up 104.2 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$32.13M (+24.3%) for the fiscal year ending Dec 2026, a step up from the -413.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$17.49M-186.3% QoQ
- Last fiscal yearDec 2025
- -$42.43M-413.7% YoY
- LTMMar 2026
- -$40.42M-143.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +10.3% | +5.8% | -4.5 pp |
| 1 year | -413.7% | +24.3% | +438.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (42.43M) USD
- Year-over-year change
- -413.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (42.43M) | -413.7% |
| FY2024 | 2024-12-31 | 13.53M | +142.2% |
| FY2023 | 2023-12-31 | (32.04M) | +49.0% |
| FY2022 | 2022-12-31 | (62.79M) | -209.7% |
| FY2021 | 2021-12-31 | (20.27M) | — |
EBITDA vs competitors
How DTIL compares with its peers on the latest reported figures
- DTIL's LTM Mar 2026 EBITDA of -$40.42M is the 3rd highest of the 7 companies compared; the peer median is -$92.66M.
- Its year-over-year change of -143.9% is the 4th highest of 6, against a peer median of -1.3%.
- EBITDA amounts to 89.7% of revenue for DTIL, versus a peer median of 304.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.15M | +154.8% | — | 41.2% | |
| LTM Mar 2026 | -$24.12M | -5355.8% | — | 16.0% | |
| LTM Mar 2026 | -$40.42M | -143.9% | — | 89.7% | |
| FY2025 | -$76.5M | — | — | 410.9% | |
| LTM Mar 2026 | -$108.82M | +2.8% | — | — | |
| LTM Mar 2026 | -$116.42M | -1.3% | — | 632.1% | |
| LTM Mar 2026 | -$168.81M | -372.8% | — | 304.0% | |
| Peer median (excluding DTIL) | -$92.66M | -1.3% | — | 304.0% | |
Competitors are the stored peer set for DTIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 115.53M | 25.1M | 48.73M | 68.7M | 34.26M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.75M |
| Gross Profit | 115.53M | 25.1M | 48.73M | 68.7M | 31.51M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 92.0% |
| Research & Development | 115.24M | 46.12M | 53.38M | 59.56M | 54.17M |
| Selling, General & Admin | 39.67M | 41.28M | 39.09M | 35.3M | 32.24M |
| Operating Expenses | 154.91M | 87.41M | 92.46M | 94.86M | 83.66M |
| Depreciation & Amortization | 10.2M | 9M | 8.26M | 4.58M | 2.75M |
| EBITDA | (20.27M) | (62.79M) | (32.04M) | 13.53M | (42.43M) |
| EBITDA Margin | -17.5% | -250.2% | -65.8% | 19.7% | -123.8% |
| Operating Income | (39.38M) | (62.31M) | (43.74M) | (26.16M) | (52.15M) |
| Operating Margin | -34.1% | -248.3% | -89.8% | -38.1% | -152.2% |
| Interest Income | 208K | 3.47M | 7.69M | 6.76M | 4.24M |
| Interest Expense | 132K | 1.11M | 2.23M | 1.78M | 1.42M |
| Other Income / Expenses | 8.77M | (10.6M) | 1.21M | 33.33M | 5.54M |
| Income Before Tax | (30.6M) | (72.91M) | (42.53M) | 7.17M | (46.61M) |
| Pre-Tax Margin | -26.5% | -290.5% | -87.3% | 10.4% | -136.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.6M) | (111.64M) | (61.32M) | 7.17M | (46.61M) |
| Net Margin | -26.5% | -444.8% | -125.8% | 10.4% | -136.0% |
| EPS (Basic) | (15.60) | (38.10) | (15.96) | 1.05 | (3.63) |
| EPS (Diluted) | (15.60) | (38.10) | (15.96) | 1.04 | (3.63) |
| Weighted Avg Shares | 1.96M | 2.93M | 3.84M | 6.83M | 12.83M |
| Weighted Avg Shares (Diluted) | 1.96M | 2.93M | 3.84M | 6.88M | 12.83M |
Precision BioSciences, Inc.
NASDAQ:DTIL
Intrinsic Alpha fair value
Locked
Current Price
$7.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.